Edwards Lifesciences Corporation · NYSE:EW
Edwards Lifesciences — 2020 Edwards Lifesciences Virtual Investor Conference
14 slides from Edwards Lifesciences's conference presentation, Dec 10, 2020
Slide 1: 2020 Investor Conference: Transcatheter Mitral and Tricuspid Therapies
2020 Investor Conference Transcatheter Mitral and Tricuspid Therapies
Slide 2: TMTT vision to lead and transform treatment of mitral and tricuspid valve disease
TMTT is guided by our vision to lead and transform treatment for patients with mitral and tricuspid valve disease To achieve this vision, TMTT is focused on 3 key value drivers Today, patients with Mitral and 1 Our portfolio of differentiated therapies Tricuspid regurgitation remain 2 Positive resul
Slide 3: TMTT is innovating a broad transcatheter portfolio
TMTT is innovating a broad transcatheter portfolio TRICUSPID MITRAL Leaflet Repair PASCAL PASCAL Ace PASCAL PASCAL Ace Annular Reduction Cardioband Cardioband Valve Replacement EVOQUE SAPIEN M3 EVOQUE CAUTION: INVESTIGATIONAL DEVICE. Limited to Investigational Use Only. 12/10/2020 3
Slide 4: Mitral Innovations: PASCAL for Leaflet Repair
Mitral Innovations: PASCAL for Leaflet Repair PASCAL Ace CE Marked in 2020 PASCAL PASCAL Ace New implant with narrower profile and spacer to achieve optimal outcomes for more patients PASCAL & PASCAL Ace share differentiated features A nitinol design to A central spacer to The ability to elongate In
Slide 5: High rates of MR reduction achieved with PASCAL from earliest experience
High rates of MR reduction are achieved with PASCAL, starting from physicians’ earliest experience CLASP IID Roll-In Data CLASP CE Mark Study Real-World Experience 73% 82% 83% Percentage of patients with Percentage of patients with Percentage of patients with MR ≤0/1+ at 30 days 1 MR ≤0/1+ at 1 year
Slide 6: Mitral Innovations: Two-platform strategy for transfemoral replacement leadership
Mitral Innovations: Two-platform strategy positions TMTT for transfemoral replacement leadership SAPIEN M3 “The strength of the Edwards mitral Leverages the Both transfemoral program is the diverse proven SAPIEN delivery systems are portfolio… valve, coupled with a to be able to treat a wide <30F no
Slide 7: Innovations & Evidence In Tricuspid Repair
Innovations & Evidence In Tricuspid Repair PASCAL: CLASP TR EFS Study Cardioband: Tri-Repair CE Mark Study PASCAL Differentiated leaflet 70% 72% repair leverages Percentage of patients with Percentage of patients with mitral platform ≥ 2 TR grade reduction1 TR ≤ moderate at 30 days2 Cardioband Stron
Slide 8: Innovations & Evidence In Tricuspid Valve Replacement
Innovations & Evidence In Tricuspid Valve Replacement EVOQUE Compassionate Use EVOQUE 88% “Having all of these Percentage of patients with options simultaneously Tricuspid platform TR ≤0/1+ at 30 days1 in your toolbox expands with three valve sizes dramatically the to address diverse number of patie
Slide 9: A dedicated team executing our high touch model
A dedicated team of talented people executing our high touch model to deliver outstanding patient outcomes The TMTT high touch model • Commitment to initial and ongoing physician training • Highly trained clinical specialists providing full case coverage and support Transforming treatment for patien
Slide 10: What to expect from TMTT in 2021
What to expect from TMTT in 2021 Additional Clinical TMTT Revenue Innovations Evidence Continued innovations on Expanding our body of Doubling TMTT revenue each platform clinical evidence, including: led by PASCAL and PASCAL Ace for both Initial clinical experience • Continued enrollment in mitral a
Slide 11: 2021 Global Sales Outlook
2021 Global Sales Outlook Headwinds Tailwinds Increasing awareness of PASCAL/PASCAL Ace leading to: Doubling Slower adoption of 2020 to PASCAL differentiation driving novel TMTT therapies ~$80M faster site activation in Europe Competition for Rapid enrollment in CLASP IID clinical trial enrollment t
Slide 12: Executive Summary
Executive Summary • Patients with Mitral and Tricuspid regurgitation remain undertreated and suffer from poor quality of life • TMTT is delivering a portfolio of therapies, backed by clinical evidence, to address the diversity and complexity of Mitral and Tricuspid disease • Doubling revenue in 2021
Slide 13: For professional use; indications and investigational device cautions
For professional use. For a listing of indications, contraindications, warnings, precautions and adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Artic
Slide 14: Edwards: Helping Patients is Our Life's Work
P| PP TN Re ND, ave Edwards Helping Patients is Our Life’s Work, and, now) pe?
Edwards Lifesciences — 2020 Edwards Lifesciences Virtual Investor Conference on 6ix